FDA Approves Pfizer's Palbociclib Combo for Metastatic Breast Cancer Maintenance
Summary
The FDA has approved Pfizer's Palbociclib combination therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. This expands the label for Palbociclib, an existing key oncology drug, into a new patient population. The approval strengthens Pfizer's oncology portfolio and offers new revenue potential from an established product.
At the time of this announcement, PFE was trading at $24.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $138.2B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.